異動解讀 | 平價減肥藥大賣助推Hims & Hers Health Inc.(HIMS)股價盤中大漲15.14%

異動解讀

02-19

Hims & Hers Health Inc.4.96%

加州舊金山醫療科技公司Hims & Hers Health Inc.（HIMS）股價今日盤中大漲15.14%,引發市場廣泛關注。

導致公司股價大漲的主要原因是,去年5月該公司以較低價格推出諾和諾德公司(Novo Nordisk)知名減肥藥物司美格魯肽的複方版本,迅速引發了消費者熱捧。自此以來,HIMS股價已累計上漲逾200%。

雖然司美格魯肽原藥供應持續短缺,但HIMS提供的替代方案的受歡迎程度持續推升了這家遠程醫療公司的業績表現,引發華爾街對其2024年第四季度財報報表持樂觀預期。不過,投行摩根士丹利則警告稱,HIMS近期漲幅過大,適當時機已錯失,給予"持平"評級並大幅下調目標價。該投行預計HIMS今年一季度業績或將遜於市場預期。

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

no data

沒有相關數據

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1167671615"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1167671615\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1167671615?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-02-19 23:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167671615","market":"us","top_or_hot":-1,"title":"異動解讀 | 平價減肥藥大賣 助推Hims & Hers Health Inc.(HIMS)股價盤中大漲15.14%","media":"異動解讀","content":"<p>加州舊金山醫療科技公司Hims & Hers Health Inc.（HIMS）股價今日盤中大漲15.14%,引發市場廣泛關注。</p>\n\n<p>導致公司股價大漲的主要原因是,去年5月該公司以較低價格推出諾和諾德公司(Novo Nordisk)知名減肥藥物司美格魯肽的複方版本,迅速引發了消費者熱捧。自此以來,HIMS股價已累計上漲逾200%。</p>\n\n<p>雖然司美格魯肽原藥供應持續短缺,但HIMS提供的替代方案的受歡迎程度持續推升了這家遠程醫療公司的業績表現,引發華爾街對其2024年第四季度財報報表持樂觀預期。不過,投行摩根士丹利則警告稱,HIMS近期漲幅過大,適當時機已錯失,給予\"持平\"評級並大幅下調目標價。該投行預計HIMS今年一季度業績或將遜於市場預期。</p>","source":"ai_movement_cn","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>異動解讀 | 平價減肥藥大賣 助推Hims & Hers Health Inc.(HIMS)股價盤中大漲15.14%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n異動解讀 | 平價減肥藥大賣 助推Hims & Hers Health Inc.(HIMS)股價盤中大漲15.14%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092702339\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">異動解讀 </p>\n<p class=\"h-time smaller\">2025-02-19 23:04</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>加州舊金山醫療科技公司Hims & Hers Health Inc.（HIMS）股價今日盤中大漲15.14%,引發市場廣泛關注。</p>\n\n<p>導致公司股價大漲的主要原因是,去年5月該公司以較低價格推出諾和諾德公司(Novo Nordisk)知名減肥藥物司美格魯肽的複方版本,迅速引發了消費者熱捧。自此以來,HIMS股價已累計上漲逾200%。</p>\n\n<p>雖然司美格魯肽原藥供應持續短缺,但HIMS提供的替代方案的受歡迎程度持續推升了這家遠程醫療公司的業績表現,引發華爾街對其2024年第四季度財報報表持樂觀預期。不過,投行摩根士丹利則警告稱,HIMS近期漲幅過大,適當時機已錯失,給予\"持平\"評級並大幅下調目標價。該投行預計HIMS今年一季度業績或將遜於市場預期。</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1167671615","we_media_id":"1092702339","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167671615","pubTimestamp":1739977483,"columns":[],"sourceInfo":{"source_id":"ai_movement_cn","name":"异动解读"},"weMediaInfo":{"media_name":"異動解讀","introduction":"个股异动一手消息解读","home_visible":1,"id":"1092702339","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"加州舊金山醫療科技公司Hims & Hers Health Inc.股價今日盤中大漲15.14%,引發市場廣泛關注。自此以來,HIMS股價已累計上漲逾200%。雖然司美格魯肽原藥供應持續短缺,但HIMS提供的替代方案的受歡迎程度持續推升了這家遠程醫療公司的業績表現,引發華爾街對其2024年第四季度財報報表持樂觀預期。不過,投行摩根士丹利則警告稱,HIMS近期漲幅過大,適當時機已錯失,給予\"持平\"評級並大幅下調目標價。該投行預計HIMS今年一季度業績或將遜於市場預期。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"HIMS & Hers Health Inc. (HIMS) stock surged 15.14% intraday on the sale of affordable weight loss pills","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"加州舊金山醫療科技公司Hims & Hers Health Inc.（HIMS）股價今日盤中大漲15.14%,引發市場廣泛關注。\n導致公司股價大漲的主要原因是,去年5月該公司以較低價格推出諾和諾德公司(Novo Nordisk)知名減肥藥物司美格魯肽的複方版本,迅速引發了消費者熱捧。自此以來,HIMS股價已累計上漲逾200%。\n雖然司美格魯肽原藥供應持續短缺,但HIMS提供的替代方案的受歡迎程度持續推升了這家遠程醫療公司的業績表現,引發華爾街對其2024年第四季度財報報表持樂觀預期。不過,投行摩根士丹利則警告稱,HIMS近期漲幅過大,適當時機已錯失,給予\"持平\"評級並大幅下調目標價。該投行預計HIMS今年一季度業績或將遜於市場預期。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0}}}

如果下載按鈕點擊無跳轉，請點擊右上角菜單選擇 “在瀏覽器打開”

立即諮詢
下載APP
掃碼下載APP